INS and type 2 diabetes mellitus: Gla‐300 was demonstrated its efficiency by lowering HbA1c levels and (significantly) decreasing the risk of hypoglycaemia for nocturnal hypoglycaemia events in patients with T2DM between 6 and 12‐month post‐treatment period in patients previously on basal insulin 15, 16, 17, 18 as well as among insulin naïve patients.